Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746448 | 0.89 | DRD2 (0.44) | DRD2DRD3GRIN2BMEN1KMT2A | |
| SCHEMBL6310196 | 0.88 | CACNA1G (0.44) | GRIN2BPOLBTMEM97SIGMAR1CACNA1G | |
| SCHEMBL6311280 | 0.84 | DRD2 (0.40) | DRD2DRD3MEN1KMT2APOLB | |
| SCHEMBL5746787 | 0.84 | HTR2C (0.46) | POLBTMEM97SIGMAR1PTGDR2 | |
| SCHEMBL6316974 | 0.81 | GRIN2B (0.47) | GRIN2BTMEM97SIGMAR1CACNA1GCACNA1H | |
| SCHEMBL5744862 | 0.78 | CYP2D6 (0.41) | POLBCACNA1GCACNA1HCACNA1IPTGDR2 | |
| SCHEMBL5748184 | 0.77 | HSD11B1 (0.41) | DRD2DRD3GRIN2BMEN1KMT2A | |
| SCHEMBL5746496 | 0.76 | GRIN2B (0.44) | DRD2DRD3GRIN2BPOLBS1PR5 | |
| SCHEMBL5747642 | 0.76 | HSD11B1 (0.44) | DRD2DRD3GRIN2BMEN1KMT2A | |
| SCHEMBL6317300 | 0.75 | PTGDR2 (0.41) | POLBTMEM97SIGMAR1CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | DRD2 701/4885DRD3 948/4885GRIN2B 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.